Genelife Clinical Research was started in 2010. For over seven years, we have been a company focused on bringing new treatment options for the society and our iinnovative methodologies and ideas are driving progress for our clients.
The company was founded on the principle of building and implementing new ideas to creating a delivery channel which will be able to reduce the timeline of Product development process with highest possible quality including pharmaceuticals, medical devices, biologics and nutraceuticals. We developed new ideas and methodologies for fast recruitment of patients Disease Surveillance Report, therapeutic area wise approach. We also developed a working model to get high quality data in low resource input. We developed services like ThemeCore Lab which is an innovative initiative taken by Genelife Clinical Research for assisting your clinical trials with expertise of a core-lab in minimal expenses.
We recognize the importance of nurturing relationships that reflect our culture of unwavering ethics and mutual respect. We have global presence with strategically located four branch offices. Genelife has managed studies ranging in size from single center/Phase I trials to multi-center/500+ subject/multi-national Phase III trials and our studies have been submitted in US FDA, TGA, BfArM and DCGI.
Genelife’s ability to deliver is demonstrated by the company’s growth from a small organization to a respected midsize CRO. This growth can be attributed mainly to the word-of- mouth endorsements of our clients. We understand the value of a satisfied client; and as loyal as our clients have been to us, we are loyal to them.
We at Genelife Clinical Research believe our responsibilities extend beyond business. That is why we established the Genelife Foundation – to provide assistance to some of the more socially and economically depressed sectors of the communities in which we work. And that is why we behave ethically and honestly in all our interactions – with our clients, our partners, patients and our employees.